登录

Zhenge Biotech Raises $70M in Series B Financing

作者: Mailman 2021-03-29 09:43
臻格生物
http://www.zgbiotech.com/
企业数据由 动脉橙 提供支持
大分子生物药CDMO技术服务供应商 | C+轮 | 运营中
中国-上海
2022-08-18
融资金额:RMB¥1亿
曜金资本
查看

(VCBeat) Mar. 22, 2021 -- Shanghai Zhenge Biotech Co., Ltd. ("Zhenge Biotech") recently announced the completion of a $70 million Series B round of financing, co-led by Qiming Venture Partners and IDG Capital, with participation from CMB International, GP Capital, CASH Capital and Hangzhou Fulin Investment. Investors from the Series A financing, including LYFE Capital, Shanghai International Group and GT Capital, also joined the investment.


Up to now, Zhenge Biotech has raised $125 million in total. The latest funds raised will be used for the construction of the commercial production base in Lin-gang Special Area, which includes a number of GMP-compliant production lines, covering an area of 45.8 mu.


Zhenge Biotech is engaged in CDMO services of macromolecular drugs. The company has already served more than 80 clients and accomplished 100 projects, including multiple clinical-stage productions, and a large number of IND applications and others, covering monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, vaccines, etc.


Zhenge Biotech has an industry-leading and experienced team of experts, and has formed a strong cooperation mode in the fields of cell line development, process development and characterization research, CMO services of clinical samples, etc. The team has developed the first domestic PD-1 antibody production process, with high yield and low price, benefiting cancer patients.


In addition to CDMO services of macromolecular drugs, Zhenge Biotech also provides the advanced cell culture platform, nutrient/metabolite analysis platform, recombinant protein analysis platform, and dry powder medium pilot production platform for its clients.


>>>>

About Qiming Venture Partners 


Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.


>>>>

About IDG Capital


IDG Capital is an investment firm that funds early- to growth-stage companies in the technology sector. Today they work with private equity and venture capital fund managers, investment advisors, and business entities from around the world. 

相关赛道 研发制造外包
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

2023创新药及供应链白皮书:解读近400起融资事件,百余条临床管线与BD并购

药明合联、上海维亚、金斯瑞蓬勃,今年为何CXO企业都想分拆上市?

【首发】抗体和重组蛋白药物CDMO皓阳生物完成超8000万元A轮融资,布局一站式药物开发

ZhenGe Biotech banks $51M in Series A Round, Focusing on Macromolecular Drugs, CDMO and Medium

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Chinagene Tech Secures ¥70 million in Series Pre-A Funding Round

2021-03-29
下一篇

Innoforce Closes ¥625M Series A Financing To Accelerate the Construction of GMP Compliant Facilities

2021-03-29